Clinical Trial Update: Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating arbaclofen for spasticity in multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Spasticity

Drugs mentioned

• Arbaclofen (arbaclofen)

Snippet

Sponsor: RVL Pharmaceuticals, Inc. | Conditions: Spasticity, Multiple Sclerosis | Phase 3 | Status: COMPLETED